Spotlight/ Insights Comparing Weight Loss/Rebound between Distinct CB1 Inhibitors Date published: September 4, 2025 2:00 pm PDT Share Copied! This research characterized advantages of nimacimab versus the small molecule CB1 inhibitor, nimacimab, in terms of weight loss and rebound. Related Documents: Measuring Efficacy and Rebound Dynamics Compared to Monlunabant: Slides